Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

PURPOSE: Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. METHODS: In this double-bli...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Support Care Cancer
Glavni autori: Takayama, Koichi, Katakami, Nobuyuki, Yokoyama, Takuma, Atagi, Shinji, Yoshimori, Kozo, Kagamu, Hiroshi, Saito, Hiroshi, Takiguchi, Yuichi, Aoe, Keisuke, Koyama, Akira, Komura, Naoyuki, Eguchi, Kenji
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917578/
https://ncbi.nlm.nih.gov/pubmed/27005463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-016-3144-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items